Targeted superparamagnetic iron oxide nanoparticles for early detection of cancer: Possibilities and challenges
Tóm tắt
Từ khóa
Tài liệu tham khảo
Frush, 2004, Computed tomography and radiation: understanding the issues, J Am Coll Radiol, 1, 113, 10.1016/j.jacr.2003.11.012
Deroose, 2007, Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging, J Nucl Med, 48, 295
Laurent, 2014, Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges, Exp Opin Drug Deliv, 1–22
Berensmeier, 2006, Magnetic particles for the separation and purification of nucleic acids, Appl Microbiol Biotechnol, 73, 495, 10.1007/s00253-006-0675-0
Laurent, 2011, Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles, Adv Colloid Interf Sci, 166, 8, 10.1016/j.cis.2011.04.003
Saei, 2014, Fe3O4 nanoparticles engineered for plasmid DNA delivery to Escherichia coli, J Nanoparticle Res, 16, 10.1007/s11051-014-2521-0
Rahman, 2015, Biomedical applications of superparamagnetic nanoparticles in molecular scale, Curr Org Chem, 19, 982, 10.2174/138527281911150610100548
Mahmoudi, 2011, Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy, Adv Drug Deliv Rev, 63, 24, 10.1016/j.addr.2010.05.006
Mahmoudi, 2010, Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine, Chem Rev, 111, 253, 10.1021/cr1001832
Wang, 2011, Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application, Quant Imaging Med Surg, 1, 35
Ahmad, 2012, Particle size dependence of relaxivity for silica-coated iron oxide nanoparticles, Curr Appl Phys, 12, 969, 10.1016/j.cap.2011.12.020
Huang, 2012, Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles, Theranostics, 2, 86, 10.7150/thno.4006
Y-w, 2005, Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging, J Am Chem Soc, 127, 5732, 10.1021/ja0422155
Xie, 2010, PET/NIRF/MRI triple functional iron oxide nanoparticles, Biomaterials, 31, 3016, 10.1016/j.biomaterials.2010.01.010
Petros, 2010, Strategies in the design of nanoparticles for therapeutic applications, Nat Rev Drug Discov, 9, 615, 10.1038/nrd2591
Fang, 2011, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv Drug Deliv Rev, 63, 136, 10.1016/j.addr.2010.04.009
Moore, 2000, Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model 1, Radiology, 214, 568, 10.1148/radiology.214.2.r00fe19568
Byrne, 2008, Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv Drug Deliv Rev, 60, 1615, 10.1016/j.addr.2008.08.005
Iagaru, 2007, Molecular imaging can accelerate anti-angiogenic drug development and testing, Nat Clin Pract Oncol, 4, 556, 10.1038/ncponc0929
Alexiou, 2000, Locoregional cancer treatment with magnetic drug targeting, Cancer Res, 60, 6641
Rosen, 2012, Iron oxide nanoparticles for targeted cancer imaging and diagnostics, Nanomedicine, 8, 275, 10.1016/j.nano.2011.08.017
Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat Rev Cancer, 2, 750, 10.1038/nrc903
Gu, 2007, Targeted nanoparticles for cancer therapy, Nano Today, 2, 14, 10.1016/S1748-0132(07)70083-X
Chester, 1995, Clinical issues in antibody design, Trends Biotechnol, 13, 294, 10.1016/S0167-7799(00)88968-4
Tiefenauer, 1993, Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging, Bioconjug Chem, 4, 347, 10.1021/bc00023a007
Brannon-Peppas, 2012, Nanoparticle and targeted systems for cancer therapy, Adv Drug Deliv Rev, 64, 206, 10.1016/j.addr.2012.09.033
Kuus-Reichel, 1994, Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?, Clin Diagn Lab Immunol, 1, 365, 10.1128/CDLI.1.4.365-372.1994
Vigor, 2010, Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells, Biomaterials, 31, 1307, 10.1016/j.biomaterials.2009.10.036
Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121
Sefah, 2010, Development of DNA aptamers using Cell-SELEX, Nat Protoc, 5, 1169, 10.1038/nprot.2010.66
Jayasena, 1999, Aptamers: an emerging class of molecules that rival antibodies in diagnostics, Clin Chem, 45, 1628, 10.1093/clinchem/45.9.1628
Huang, 2008, Cancer cell targeting using multiple aptamers conjugated on nanorods, Anal Chem, 80, 567, 10.1021/ac702322j
Zhao, 2009, Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells, Analyst, 134, 1808, 10.1039/b904476k
Li, 2014, In vitro selection of DNA aptamers for metastatic breast cancer cell recognition and tissue imaging, Anal Chem, 86, 6596, 10.1021/ac501205q
Kim, 2011, In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells, Nucleic Acids Ther, 21, 173, 10.1089/nat.2011.0283
Li, 2009, Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEX, J Pathol, 218, 327, 10.1002/path.2543
Song, 2013, Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture, Anal Chem, 85, 4141, 10.1021/ac400366b
Kimura, 2009, Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects, Cancer Res, 69, 2435, 10.1158/0008-5472.CAN-08-2495
Li, 2010, Glycan changes: cancer metastasis and anti-cancer vaccines, J Biosci, 35, 665, 10.1007/s12038-010-0073-8
Singh, 2011, Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy, PLoS One, 6, 10.1371/journal.pone.0026803
Wagstaff, 2006, Protein transduction: cell penetrating peptides and their therapeutic applications, Curr Med Chem, 13, 1371, 10.2174/092986706776872871
Sudimack, 2000, Targeted drug delivery via the folate receptor, Adv Drug Deliv Rev, 41, 147, 10.1016/S0169-409X(99)00062-9
Weitman, 1992, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, Cancer Res, 52, 3396
Reimer, 1998, Hepatic MRI with SPIO: detection and characterization of focal liver lesions, Eur Radiol, 8, 1198, 10.1007/s003300050535
Sun, 2002, Size-controlled synthesis of magnetite nanoparticles, J Am Chem Soc, 124, 8204, 10.1021/ja026501x
Lee, 2007, Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging, Nat Med, 13, 95, 10.1038/nm1467
Zhao, 2013, Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging, Nat Commun, 4, 10.1038/ncomms3266
Li, 2015, Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma, World J Gastroenterol, 21, 4275, 10.3748/wjg.v21.i14.4275
Maeng, 2010, Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer, Biomaterials, 31, 4995, 10.1016/j.biomaterials.2010.02.068
Pilapong, 2015, Magnetic-EpCAM nanoprobe as a new platform for efficient targeting, isolating and imaging hepatocellular carcinoma, RSC Adv, 5, 30687, 10.1039/C5RA01566A
Israeli, 1994, Expression of the prostate-specific membrane antigen, Cancer Res, 54, 1807
Chang, 1999, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res, 59, 3192
Smith-Jones, 2003, Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor, J Nucl Med, 44, 610
Bander, 2003, Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen, J Urol, 170, 1717, 10.1097/01.ju.0000091655.77601.0c
Abdolahi, 2013, Synthesis and in vitro evaluation of MR molecular imaging probes using J591 mAb‐conjugated SPIONs for specific detection of prostate cancer, Contrast Media Mol Imaging, 8, 175, 10.1002/cmmi.1514
Holland, 2010, 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo, J Nucl Med, 51, 1293, 10.2967/jnumed.110.076174
Wang, 2008, Superparamagnetic iron oxide nanoparticle–aptamer bioconjugates for combined prostate cancer imaging and therapy, ChemMedChem, 3, 1311, 10.1002/cmdc.200800091
Cho, 2010, Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment, ACS Nano, 4, 5398, 10.1021/nn101000e
Ghosh, 2012, M13-templated magnetic nanoparticles for targeted in vivo imaging of prostate cancer, Nat Nanotechnol, 7, 677, 10.1038/nnano.2012.146
Gao, 2012, Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy, Int J Nanomedicine, 7, 4037, 10.2147/IJN.S32804
Serres, 2012, Molecular MRI enables early and sensitive detection of brain metastases, Proc Natl Acad Sci, 109, 6674, 10.1073/pnas.1117412109
Krol, 2012, Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier, Chem Rev, 113, 1877, 10.1021/cr200472g
Cao, 2014, Targeted in vivo imaging of microscopic tumors with ferritin‐based nanoprobes across biological barriers, Adv Mater, 26, 2566, 10.1002/adma.201304544
Krol, 2013, Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier, Chem Rev, 113, 1877, 10.1021/cr200472g
Varallyay, 2002, Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors, Am J Neuroradiol, 23, 510
Neuwelt, 2004, Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours, Neuropathol Appl Neurobiol, 30, 456, 10.1111/j.1365-2990.2004.00557.x
Manninger, 2005, An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions, Am J Neuroradiol, 26, 2290
Huse, 2010, Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma, Nat Rev Cancer, 10, 319, 10.1038/nrc2818
Giese, 2001, Treatment of malignant glioma: a problem beyond the margins of resection, J Cancer Res Clin Oncol, 127, 217, 10.1007/s004320000188
Lyons, 2002, Chlorotoxin, a scorpion‐derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin, Glia, 39, 162, 10.1002/glia.10083
Soroceanu, 1998, Use of chlorotoxin for targeting of primary brain tumors, Cancer Res, 58, 4871
Meng, 2007, Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents, Acta Pharmacol Sin, 28, 2019, 10.1111/j.1745-7254.2007.00661.x
Sun, 2008, In vivo MRI detection of gliomas by chlorotoxin‐conjugated superparamagnetic nanoprobes, Small, 4, 372, 10.1002/smll.200700784
Shevtsov, 2015, Brain tumor magnetic targeting and biodistribution of superparamagnetic iron oxide nanoparticles linked with 70-kDa heat shock protein study by nonlinear longitudinal response, J Magn Magn Mater, 388, 123, 10.1016/j.jmmm.2015.04.030
Wagner, 1994, Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis, Adv Drug Deliv Rev, 14, 113, 10.1016/0169-409X(94)90008-6
Ciechanover, 1983, Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents, J Biol Chem, 258, 9681, 10.1016/S0021-9258(17)44551-0
Durgadas, 2011, Fluorescent and superparamagnetic hybrid quantum clusters for magnetic separation and imaging of cancer cells from blood, Nanoscale, 3, 4780, 10.1039/c1nr10900f
Jiang, 2013, pH/temperature sensitive magnetic nanogels conjugated with Cy5. 5-labeled lactoferrin for MR and fluorescence imaging of glioma in rats, Biomaterials, 34, 7418, 10.1016/j.biomaterials.2013.05.078
Jansen, 2010, Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers, Lancet Neurol, 9, 717, 10.1016/S1474-4422(10)70105-8
Shevtsov, 2014, superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (sPION–egF) for targeting brain tumors, Int J Nanomedicine, 9, 273, 10.2147/IJN.S55118
Kohler, 2006, Methotrexate‐immobilized poly (ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery, Small, 2, 785, 10.1002/smll.200600009
Sun, 2006, Folic acid‐PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI, J Biomed Mater Res A, 78, 550, 10.1002/jbm.a.30781
Kohler, 2005, Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells, Langmuir, 21, 8858, 10.1021/la0503451
Leuschner, 2006, LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases, Breast Cancer Res Treat, 99, 163, 10.1007/s10549-006-9199-7
Chen, 2009, Targeted herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI, JBIC J Biol Inorg Chem, 14, 253, 10.1007/s00775-008-0445-9
Artemov, 2003, MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles, Magn Reson Med, 49, 403, 10.1002/mrm.10406
Huh, 2005, In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals, J Am Chem Soc, 127, 12387, 10.1021/ja052337c
Kievit, 2012, Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs, ACS Nano, 6, 2591, 10.1021/nn205070h
Kresse, 1998, Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways, Magn Reson Med, 40, 236, 10.1002/mrm.1910400209
Sipkins, 1998, Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging, Nat Med, 4, 623, 10.1038/nm0598-623
Zhang, 2007, Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner, Cancer Res, 67, 1555, 10.1158/0008-5472.CAN-06-1668
Pasqualini, 1997, av Integrins as receptors for tumor targeting by circulating ligands, Nat Biotechnol, 15, 542, 10.1038/nbt0697-542
Brooks, 1994, Requirement of vascular integrin alpha v beta 3 for angiogenesis, Science, 264, 569, 10.1126/science.7512751
Montet, 2006, Nanoparticle imaging of integrins on tumor cells, Neoplasia, 8, 214, 10.1593/neo.05769
Xie, 2008, Ultrasmall c (RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin αvβ3-rich tumor cells, J Am Chem Soc, 130, 7542, 10.1021/ja802003h
Yan, 2013, Anti-αvβ3 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis, Int J Nanomedicine, 8, 245
Huang, 2013, Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting, ACS Appl Mater Interfaces, 5, 4632, 10.1021/am400713j
Gong, 2014, A dual ligand targeted nanoprobe with high MRI sensitivity for diagnosis of breast cancer, Chin J Polym Sci, 32, 321, 10.1007/s10118-014-1399-8
Foy, 2010, Optical imaging and magnetic field targeting of magnetic nanoparticles in tumors, ACS Nano, 4, 5217, 10.1021/nn101427t
Williams B, Alexander CM, Lindvall C, Mcconnell N. Mammary stem cell marker. US Patent 20,070,280,948; 2007.
Williams BO, Lindvall C. Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods. Google Patents; 2009.
Hatabu, 1999, T2* and proton density measurement of normal human lung parenchyma using submillisecond echo time gradient echo magnetic resonance imaging, Eur J Radiol, 29, 245, 10.1016/S0720-048X(98)00169-7
Kuethe, 2007, Short data‐acquisition times improve projection images of lung tissue, Magn Reson Med, 57, 1058, 10.1002/mrm.21230
Branca, 2010, Molecular MRI for sensitive and specific detection of lung metastases, Proc Natl Acad Sci, 107, 3693, 10.1073/pnas.1000386107
Jiang, 2009, Noninvasively characterizing the different αvβ3 expression patterns in lung cancers with RgD-UsPIO using a clinical 3.0T MR scanner, Int J Nanomedicine, 4, 241, 10.2147/IJN.S7519
Zhang, 2012, Mono-dispersed high magnetic resonance sensitive magnetite nanocluster probe for detection of nascent tumors by magnetic resonance molecular imaging, Nanomedicine, 8, 996, 10.1016/j.nano.2011.11.013
Levin, 2008, Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology*†, CA Cancer J Clin, 58, 130, 10.3322/CA.2007.0018
Toma, 2005, Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma, Br J Cancer, 93, 131, 10.1038/sj.bjc.6602668
Kitamura, 1993, The role of monoclonal antibody A7 as a drug modifier in cancer therapy, Cancer Immunol Immunother, 36, 177, 10.1007/BF01741089
He, 2014, Lectin-conjugated Fe2O3@ Au core@ shell nanoparticles as dual mode contrast agents for in vivo detection of tumor, Mol Pharm, 11, 738, 10.1021/mp400456j
Jiang, 2010, Synthesis of biotinylated α-d-mannoside or N-acetyl β-d-glucosaminoside decorated gold nanoparticles: study of their biomolecular recognition with Con A and WGA lectins, Bioconjug Chem, 21, 521, 10.1021/bc900431p
Kirui, 2013, Targeted near-IR hybrid magnetic nanoparticles for in vivo cancer therapy and imaging, Nanomedicine, 9, 702, 10.1016/j.nano.2012.11.009
Deckert, 2003, A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy, Br J Cancer, 88, 937, 10.1038/sj.bjc.6600751
Zou, 2010, Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release, Mol Pharm, 7, 1974, 10.1021/mp100273t
Farrera-Sinfreu, 2005, Cell-penetrating cis-γ-amino-l-proline-derived peptides, J Am Chem Soc, 127, 9459, 10.1021/ja051648k
Cavalli, 2012, Efficient γ-amino-proline-derived cell penetrating peptide–superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents, Chem Commun, 48, 5322, 10.1039/c2cc17937g
Yu, 2013, Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells, Nanoscale, 5, 178, 10.1039/C2NR32145A
Li, 2014, Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging, Biomaterials, 35, 3666, 10.1016/j.biomaterials.2014.01.011
Liao, 2011, Polymeric liposomes-coated superparamagnetic iron oxide nanoparticles as contrast agent for targeted magnetic resonance imaging of cancer cells, Langmuir, 27, 3100, 10.1021/la1050157
Shahbazi-Gahrouei, 2013, Superparamagnetic iron oxide-C595: potential MR imaging contrast agents for ovarian cancer detection, J Med Phys Assoc Med Physicists India, 38, 198
Shahbazi-Gahrouei, 2013, Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging, Sci World J, 2013, 10.1155/2013/609151
Gao, 2011, Affibody-based nanoprobes for HER2-expressing cell and tumor imaging, Biomaterials, 32, 2141, 10.1016/j.biomaterials.2010.11.053
Lutz, 2014, Ultrasound molecular imaging in a human CD276 expression–modulated murine ovarian cancer model, Clin Cancer Res, 20, 1313, 10.1158/1078-0432.CCR-13-1642
Welsh, 2001, Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer, Proc Natl Acad Sci, 98, 1176, 10.1073/pnas.98.3.1176
Suwa, 1998, Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody, Int J Cancer, 75, 626, 10.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5
El-Boubbou, 2010, Magnetic glyco-nanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging, J Am Chem Soc, 132, 4490, 10.1021/ja100455c
Pilobello, 2007, Deciphering the glycocode: the complexity and analytical challenge of glycomics, Curr Opin Chem Biol, 11, 300, 10.1016/j.cbpa.2007.05.002
Herr, 2006, Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells, Anal Chem, 78, 2918, 10.1021/ac052015r
Bhana, 2015, Nanotechnology for enrichment and detection of circulating tumor cells, Nanomedicine, 10, 1973, 10.2217/nnm.15.32
Vu-Quang, 2011, Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo, Acta Biomater, 7, 3935, 10.1016/j.actbio.2011.06.044
Lim, 2011, TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model, Acad Radiol, 18, 504, 10.1016/j.acra.2010.10.017
Vu-Quang, 2012, Immune cell-specific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging, Carbohydr Polym, 87, 1159, 10.1016/j.carbpol.2011.08.091
Peiris, 2012, Imaging metastasis using an integrin-targeting chain-shaped nanoparticle, ACS Nano, 6, 8783, 10.1021/nn303833p
Ocak, 2015, Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model, Mol Pharm, 12, 542, 10.1021/mp500628g
Sroka, 2009, Human cell surface receptors as molecular imaging candidates for metastatic prostate cancer, Open Prostate Cancer J, 2, 59, 10.2174/1876822900902010059
Mirshafiee, 2016, Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake, Biomaterials, 75, 295, 10.1016/j.biomaterials.2015.10.019
Mahmoudi, 2014, Variation of protein corona composition of gold nanoparticles following plasmonic heating, Nano Lett, 14, 6, 10.1021/nl403419e
Mahmoudi, 2011, Protein–nanoparticle interactions: opportunities and challenges, Chem Rev, 111, 5610, 10.1021/cr100440g
Casals, 2010, Time evolution of the nanoparticle protein corona, ACS Nano, 4, 3623, 10.1021/nn901372t
Lundqvist, 2008, Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts, Proc Natl Acad Sci, 105, 14265, 10.1073/pnas.0805135105
Mahmoudi, 2009, Cell toxicity of superparamagnetic iron oxide nanoparticles, J Colloid Interface Sci, 336, 510, 10.1016/j.jcis.2009.04.046
Cedervall, 2007, Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles, Proc Natl Acad Sci, 104, 2050, 10.1073/pnas.0608582104
Ghavami, 2013, Plasma concentration gradient influences the protein corona decoration on nanoparticles, RSC Adv, 3, 1119, 10.1039/C2RA22093H
Mahmoudi, 2013, Variation of protein corona composition of gold nanoparticles following plasmonic heating, Nano Lett, 14, 6, 10.1021/nl403419e
Mahmoudi, 2013, Slight temperature changes affect protein affinity and cellular uptake/toxicity of nanoparticles, Nanoscale, 5, 3240, 10.1039/c3nr32551b
Hajipour, 2015, Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide, Nanoscale, 7, 8978, 10.1039/C5NR00520E
Hajipour, 2014, Personalized protein coronas: a “key” factor at the nanobiointerface, Biomater Sci, 2, 1210, 10.1039/C4BM00131A
Caracciolo, 2015, Lipid composition: a “key factor” for the rational manipulation of the liposome-protein corona by liposome design, RSC Adv, 5, 5967, 10.1039/C4RA13335H
Caracciolo, 2014, Size and charge of nanoparticles following incubation with human plasma of healthy and pancreatic cancer patients, Colloids Surf B: Biointerfaces, 123, 673, 10.1016/j.colsurfb.2014.10.008
Salvati, 2013, Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nat Nanotechnol, 8, 137, 10.1038/nnano.2012.237
Mirshafiee, 2013, Protein corona significantly reduces active targeting yield, Chem Commun, 49, 2557, 10.1039/c3cc37307j
Mahmoudi, 2015, Crucial role of the protein corona for the specific targeting of nanoparticles, Nanomedicine, 10, 215, 10.2217/nnm.14.69
Moyano, 2014, Fabrication of corona-free nanoparticles with tunable hydrophobicity, ACS Nano, 8, 6748, 10.1021/nn5006478
Amiri, 2013, Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles, Nanoscale, 5, 8656, 10.1039/c3nr00345k
Shang, 2007, pH-dependent protein conformational changes in albumin: gold nanoparticle bioconjugates: a spectroscopic study, Langmuir, 23, 2714, 10.1021/la062064e
Mahmoudi, 2011, Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles, Nanoscale, 3, 1127
Wu, 2008, TiO2 nanoparticles promote β-amyloid fibrillation in vitro, Biochem Biophys Res Commun, 373, 315, 10.1016/j.bbrc.2008.06.035
Saei, 2014, Toxicity of nanoparticles. Nanoparticles for delivery of biotherapeutics, Future Med, 1, 112
You, 2006, Modulation of the catalytic behavior of α-chymotrypsin at monolayer-protected nanoparticle surfaces, J Am Chem Soc, 128, 14612, 10.1021/ja064433z
You, 2005, Contrasting effects of exterior and interior hydrophobic moieties in the complexation of amino acid functionalized gold clusters with α-chymotrypsin, Org Lett, 7, 5685, 10.1021/ol052367k
De, 2008, Synthetic “chaperones”: nanoparticle-mediated refolding of thermally denatured proteins, Chem Commun, 3504–6
Walkey, 2012, Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake, J Am Chem Soc, 134, 2139, 10.1021/ja2084338
Nagayama, 2007, Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics, Int J Pharm, 342, 215, 10.1016/j.ijpharm.2007.04.036
Rubel, 2001, Fibrinogen promotes neutrophil activation and delays apoptosis, J Immunol, 166, 2002, 10.4049/jimmunol.166.3.2002
Sitrin, 1998, Fibrinogen activates NF-κB transcription factors in mononuclear phagocytes, J Immunol, 161, 1462, 10.4049/jimmunol.161.3.1462
Ruge, 2011, Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A, Nanomed Nanotechnol Biol Med, 7, 690, 10.1016/j.nano.2011.07.009
Saie, 2015, Engineering the nanoparticle-protein interface for cancer therapeutics, 245
Tenzer, 2013, Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat Nanotechnol, 8, 772, 10.1038/nnano.2013.181
Hu, 2011, Protein corona-mediated mitigation of cytotoxicity of graphene oxide, ACS Nano, 5, 3693, 10.1021/nn200021j
Hamad, 2010, Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere–serum interface: implications for stealth nanoparticle engineering, ACS Nano, 4, 6629, 10.1021/nn101990a
Kah, 2012, Exploiting the protein corona around gold nanorods for loading and triggered release, ACS Nano, 6, 6730, 10.1021/nn301389c
Mahmoudi, 2013, Temperature: the “ignored” factor at the NanoBio interface, ACS Nano, 7, 6555, 10.1021/nn305337c
Högemann-Savellano, 2003, The transferrin receptor: a potential molecular imaging marker for human cancer, Neoplasia, 5, 495, 10.1016/S1476-5586(03)80034-9
Srivastava, 2003, Scavenger receptor class B type I expression in murine brain and regulation by estrogen and dietary cholesterol, J Neurol Sci, 210, 11, 10.1016/S0022-510X(03)00006-6
Zannis, 2006, Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL, J Mol Med, 84, 276, 10.1007/s00109-005-0030-4